Global Endowment Management’s Spyre Therapeutics SYRE Stock Holding History

Global Endowment Management’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Sell	12,123 -6,061	-33%	-$442K	0.11%	52
2026 Q1	$917K	Hold	18,184	–	–	0.1%	56
2025 Q4	$596K	Hold	18,184	–	–	0.07%	72
2025 Q3	$305K	Hold	18,184	–	–	0.04%	119
2025 Q2	$272K	Hold	18,184	–	–	0.04%	114
2025 Q1	$293K	Hold	18,184	–	–	0.04%	111
2024 Q4	$423K	Hold	18,184	–	–	0.05%	117
2024 Q3	$535K	Hold	18,184	–	–	0.05%	107
2024 Q2	$428K	Hold	18,184	–	–	0.05%	115
2024 Q1	$690K	Sell	18,184 -495,252	-96%	-$14.3M	0.07%	93
2023 Q4	$11M	Buy	+513,436	New	+$7.07M	1.23%	14

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Global Endowment Management's SYRE Position: Q2 2026 in Review

Global Endowment Management reduced its Spyre Therapeutics (SYRE) stake by 33% in Q2 2026, selling an estimated $442K and leaving 12,123 shares worth $1.08M. The position accounts for 0.11% of the portfolio, ranked #52.

Global Endowment Management first reported a position in SYRE in Q4 2023 and has held it in 11 quarters since. The position peaked at $11M in Q4 2023. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Global Endowment Management held 12,123 shares of Spyre Therapeutics worth $1.08M as of Q2 2026.
Global Endowment Management sold 6,061 Spyre Therapeutics shares in Q2 2026, an estimated $442K.
Spyre Therapeutics made up 0.11% of Global Endowment Management's portfolio in Q2 2026, its #52 holding.
Global Endowment Management first reported a position in Spyre Therapeutics in Q4 2023 and has held it in 11 quarters since.
Global Endowment Management's Spyre Therapeutics position peaked at $11M in Q4 2023.
266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Global Endowment Management's 13F filing for Q2 2026, filed 14 Aug 2026.